BioMedNewsBreaks

TuesdayMay 07, 2024 2:39 pm

BioMedNewsBreaks — FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Marks Important Step in Advancing Lucid-21-302

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, today announces the submission to ethics of a trial. Entitled “A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of Lucid-21-302 in Healthy Adult Participants,” the clinical trial application is submitted for review by a human ethics review committee (“HREC”) in Australia. The step is necessary to obtain permission to initiate the multiple ascending dose (“MAD”) trial, which follows the Phase-1 single ascending dose (“SAD”)…

Continue Reading

TuesdayMay 07, 2024 2:12 pm

BioMedNewsBreaks – Sigyn Therapeutics Inc. (SIGY) Announces Publication of Article on Emerging Candidate – Sigyn Therapy(TM)

Sigyn Therapeutics (OTCQB: SIGY), a development-stage medical technology company, today announced that it has published an article entitled: “Sigyn Therapy(TM), an Emerging Candidate to Address Endotoxemia, Sepsis and Drug-Resistant Viral & Bacterial Infections.” “When we designed Sigyn Therapy, we envisioned a medical device that could overcome the limitations of previous blood purification technologies to treat life-threatening conditions that are beyond the reach of drugs. Along with the efforts of our dedicated team, contributions from science advisors, collaborators and shareholders have helped to advance our vision toward reality,” said Jim Joyce, co-founder and CEO of Sigyn Therapeutics. “Consider that in the…

Continue Reading

TuesdayMay 07, 2024 1:17 pm

BioMedNewsBreaks — PaxMedica Inc. (PXMD) Continues Advancement of PAX-101 Regulatory Strategy

PaxMedica (OTC: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, has issued a corporate update in light of its transition off the NASDAQ stock market, emphasizing this change will not affect the company’s commitment to advancing treatments for neurological disorders. “Our determination to progress with the NDA submission for PAX-101 remains unaffected, as does our commitment to our clinical program to further explore the potential for anti-purinergic therapies to address the core symptoms of autism spectrum disorder (‘ASD’),” said Howard Weisman, CEO of PaxMedica, further emphasizing the company’s efforts to advance healthcare solutions globally. “We are not…

Continue Reading

MondayMay 06, 2024 3:20 pm

BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Announces Nasdaq Delisting Notification and Appeal, ADS Ratio Change

Scinai Immunotherapeutics (NASDAQ: SCNI) is a biopharmaceutical company focused on developing inflammation and immunology (“I&I”) biological products and providing CDMO services through its Scinai Bioservices business unit. The company today announced that it has received a staff determination letter on April 30, 2024, from the Listing Qualifications Department of the Nasdaq Stock Market LLC. In the letter, Nasdaq notified the company that, due to its non-compliance with the minimum $1.00 bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2), the company's American Depositary Shares (“ADSs”) would be scheduled for delisting from the Nasdaq Capital Market and would be suspended…

Continue Reading

MondayMay 06, 2024 3:05 pm

BioMedNewsBreaks — Aileron Therapeutics Inc. (NASDAQ: ALRN) Closes Underwritten Registered Direct Offering

Aileron Therapeutics (NASDAQ: ALRN) is a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications. The company has announced the closing of its underwritten registered direct offering priced at-the-market under Nasdaq rules of 4,273,505 shares of its common stock and accompanying warrants to purchase an aggregate of 4,273,505 shares of common stock. Aileron secured aggregate gross proceeds of approximately $20 million, before deducting underwriting discounts and commissions and other offering expenses and excluding any proceeds that may be received from exercise of the warrants. Titan Partners Group, a…

Continue Reading

MondayMay 06, 2024 8:30 am

BioMedNewsBreaks — NanoViricides Inc. (NYSE American: NNVC) Reports that NV-387 Shows Strong Activity Against Influenza A

NanoViricides (NYSE American: NNVC), a global leader in broad-spectrum antiviral nanomedicines, is reporting that the ultra-broad antiviral activity spectrum of NV-387 includes influenza A viruses, possibly including bird flu H5N1 virus as well. According to the announcement, the company performed a lethal animal model of lung infection by influenza A/H3N2 virus that indicated NV-387 showed superior antiviral effects compared to three approved anti-influenza drugs: Oseltamivir (Tamiflu[R], Roche), Peramivir (Rapivab[R], Biocryst), and Baloxivir (Xofluza[R], Shionogi, Roche). “We are pleasantly surprised by this extremely broad and strong antiviral activity of NV-387,” said NanoViricides president and executive chair Anil R. Diwan, PhD, in…

Continue Reading

ThursdayMay 02, 2024 2:36 pm

BioMedNewsBreaks – Longeveron Inc. (NASDAQ: LGVN) Schedules Release of Q1 2024 Financial Results, Earnings Conference Call/Webcast

Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (“HLHS”), Alzheimer’s disease and Aging-Related Frailty, will be releasing its first-quarter 2024 financial results this month. The company announced that it will release the report, along with a business update, on May 14, 2024, after the U.S. markets close. The company has also scheduled a conference call and webcast to discuss the release; the call will begin at 5 p.m. ET, also on May 14. Those wishing to access the call can dial 877-407-0789 and use the conference…

Continue Reading

WednesdayMay 01, 2024 2:27 pm

BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) Spotlighted in a Recent ‘From Lab to Launch’ Podcast Release

Clene (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc. is a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases. Rob Etherington, President, Director and CEO of Clene, was featured in a recent release of From Lab to Launch, a podcast sharing the inspiring stories of founders, investors, scientists, engineers and pioneers in the life sciences sector. The podcast, hosted by Meg Sinclair, is available for on-demand listening on From Lab to Launch. During the interview, Etherington discussed Clene’s work to address the critical unmet medical…

Continue Reading

TuesdayApr 30, 2024 1:00 pm

BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Enters Agreement to Conduct Clinical Trial to Assess Safety, Efficacy of unbuzzd(TM)

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, has entered into agreement with Florida-based Applied Science and Performance Institute (“ASPI”). The agreement outlines plans to conduct a randomized, double-blind, placebo-controlled crossover study designed to assess the safety and efficacy of FSD Pharma’s unbuzzd(TM). The study will be conducted with healthy volunteers in an induced state of alcohol intoxication. A unique dietary supplement with natural ingredients, vitamins and Generally Recognized as Safe (“GRAS”) ingredients, unbuzzd exhibits potential…

Continue Reading

TuesdayApr 30, 2024 11:36 am

BioMedNewsBreaks – HealthLynked Corp. (HLYK) Announces Strategic Partnership with IBN

HealthLynked (OTCQB: HLYK), a trailblazer in healthcare technology, today announced that it has joined forces with IBN, a leading financial news and publishing company, to enhance HYLK shareholder communication and spotlight the company’s unique technologies for improving healthcare. The collaboration is set to enhance HealthLynked’s corporate communication efforts and elevate its visibility within the investment community. As part of the client partner relationship, IBN will utilize its extensive investor-based distribution network of 5,000+ key syndication outlets, various newsletters, social media channels, wire services via InvestorWire, blogs and other outreach tools to IBN will leverage its investor based distribution network of…

Continue Reading